GSK to sell two travel vaccines to Danish biotech firm

  • Mon,21 Oct 2019 09:18:44 AM



(Reuters) - GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).

The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, by the British drugmaker includes milestone payments of up to 495 million euros.

 

 

 

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur)

Leave a Comment

Title : GSK to sell two travel vaccines to Danish biotech firm

 
You have 2000 characters left.